Immunotech Biopharm Ltd (HK:6978) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Immunotech Biopharm Ltd has announced the transfer of its RMB300 million Convertible Bonds from Tasly (Hong Kong) Pharmaceutical Investment Limited to Tibet Jiaze Venture Capital Co., Ltd, pending several conditions. The transfer reflects strategic movements in the financial market and highlights the venture capital interest in biotech industries. Upon completion, the bonds’ terms will remain unchanged, maintaining the financial stability of the arrangement.
For further insights into HK:6978 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Amazon (NASDAQ:AMZN) Carries on With Grocery Store Plans
- Ford (NYSE:F) Faces Multiple Product Recalls
- ‘Favorable Trends,’ Says Top Investor About Super Micro Computer Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
